Cubist Systematic Strategies LLC Acquires 35,394 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

Cubist Systematic Strategies LLC lifted its holdings in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 43.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 117,404 shares of the company's stock after buying an additional 35,394 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.37% of Delcath Systems worth $1,414,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Quarry LP acquired a new stake in shares of Delcath Systems during the fourth quarter worth $34,000. Quantbot Technologies LP bought a new position in shares of Delcath Systems in the 4th quarter valued at about $66,000. Boothbay Fund Management LLC boosted its holdings in shares of Delcath Systems by 30.2% during the 4th quarter. Boothbay Fund Management LLC now owns 34,749 shares of the company's stock worth $418,000 after buying an additional 8,061 shares during the period. Riverwater Partners LLC boosted its holdings in shares of Delcath Systems by 46.2% during the 4th quarter. Riverwater Partners LLC now owns 27,229 shares of the company's stock worth $328,000 after buying an additional 8,601 shares during the period. Finally, Barclays PLC bought a new stake in shares of Delcath Systems during the 3rd quarter worth about $104,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. HC Wainwright lifted their price objective on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. Craig Hallum boosted their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a report on Friday, January 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $22.75.

Delcath Systems Trading Down 2.6%

DCTH stock opened at $14.45 on Tuesday. Delcath Systems, Inc. has a 12 month low of $5.30 and a 12 month high of $16.97. The firm has a market capitalization of $483.11 million, a P/E ratio of -10.70 and a beta of 0.72. The firm has a 50 day moving average of $12.33 and a 200-day moving average of $12.62.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The business had revenue of $19.80 million for the quarter, compared to analysts' expectations of $16.83 million. Sell-side analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.